Evidence map›Paper›PMID 33028943›Full record

ReviewProstate cancer and prostatic diseases2021

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Arif Hussain, Abhishek Tripathi, Christopher Pieczonka, Diane Cope, Andrea McNatty, Christopher Logothetis, Theresa Guise

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Arif HussainUniversity of Maryland Greenebaum Cancer Center and Baltimore VA Medical System, Baltimore, MD, USA. ahussain@som.maryland.edu.ORCID http://orcid.org/0000-0001-8485-4406
Abhishek TripathiUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Christopher PieczonkaAMP Urology, Syracuse, NY, USA.ORCID http://orcid.org/0000-0002-2531-7587
Diane CopeFlorida Cancer Specialists and Research Institute, Fort Myers, FL, USA.
Andrea McNattyMayo Clinic AZ, Scottsdale, AZ, USA.
Christopher LogothetisMD Anderson Cancer Center, Houston, TX, USA.
Theresa GuiseIndiana University School of Medicine, Indianapolis, IN, USA.
Florida Cancer Specialists & Research Institute · USIndiana University School of MedicineMayo Clinic in Arizona · USThe University of Texas MD Anderson Cancer Center · USUniversity of Maryland, Baltimore · USUniversity of Oklahoma Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy. Despite absence of metastatic disease, patients with nonmetastatic castrate-resistant prostate cancer receiving newer androgen receptor inhibitors can experience decreased bone mineral density. A systematic approach to bone health care has been hampered by a simplistic view that does not account for heterogeneity among prostate cancer patients or treatments they receive. This review aims to raise awareness in oncology and urology communities regarding the complexity of bone health, and to provide a framework for management strategies for patients with nonmetastatic castrate-resistant prostate cancer receiving androgen receptor inhibitor treatment.

methodsWe searched peer-reviewed literature on the PubMed database using key words "androgen-deprivation therapy," "androgen receptor inhibitors," "bone," "bone complications," and "nonmetastatic prostate cancer" from 2000 to present.

resultsWe discuss how androgen inhibition affects bone health in patients with nonmetastatic castrate-resistant prostate cancer. We present data from phase 3 trials on the three approved androgen receptor inhibitors with regard to effects on bone. Finally, we present management strategies for maintenance of bone health.

conclusionsIn patients with nonmetastatic castrate-resistant prostate cancer, aging, and antiandrogen therapy contribute to bone fragility. Newer androgen receptor inhibitors were associated with falls or fractures in a small subset of patients. Management guidelines include regular assessment of bone density, nutritional guidance, and use of antiresorptive bone health agents when warranted.

Indexed as

Bone DensityAndrogen AntagonistsBone DiseasesClinical Trials, Phase III as TopicHumansMaleProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAndrogen AntagonistsAR protein, humanReceptors, Androgen

Identifiers

PMID33028943
PMCPMC8134041
OpenAlexW3092471450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.